Published in Healthcare Mergers, Acquisitions and Ventures Week, November 24th, 2007
"The results of the Albuferon non-responder study demonstrated that Albuferon treatment at doses up to 1800 mcg every two weeks had an acceptable long-term safety profile and produced an overall sustained virologic response (SVR) rate of 17% in these patients," said David Nelson, M.D., Associate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.